Research Article
Application of Certain π-Acceptors for the Spectrophotometric Determination of Alendronate Sodium in Pharmaceutical Bulk and Dosage Forms
Table 3
Determination of alendronate sodium in pharmaceutical formulations by the proposed and reference [
23] methods.
| Sample | Recovery ± S.D. | Official method | Method A | Method B |
| Fosamax tablets | 99.60 ± 0.83 | 99.75 ± 0.78 | 99.87 ± 0.69 | | | 0.24 | 0.60 | | | 1.15 | 1.14 | Ostepor tablets | 100.02 ± 0.46 | 99.56 ± 0.53 | 99.92 ± 0.53 | | | 1.24 | 0.54 | | | 1.58 | 1.28 | Bongard tablets | 99.75 ± 0.63 | 99.90 ± 0.41 | 100.05 ± 0.61 | | | 1.42 | 0.52 | | | 0.75 | 1.13 | Bonate tablets | 100.12 ± 0.52 | 100.01 ± 0.57 | 99.89 ± 0.68 | | | 1.28 | 0.34 | | | 1.22 | 1.12 |
|
|
*Average of 3 independent analyses.
|